Masanori Noguchi

Masanori Noguchi

Auto-generated profile, based on publicly available information

Masanori Noguchi

Department of Urology, Kurume University School of Medicine, Kurume, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2010 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MNMasanori Noguchi
Masanori Noguchi
TKTatsuyuki Kakuma
Tatsuyuki Kakuma
HUHirotsugu Uemura
Hirotsugu Uemura
YNYasutomo Nasu
Yasutomo Nasu
HKHiromi Kumon
Hiromi Kumon
KIKyogo Itoh
Kyogo Itoh

30 November 2012 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MNMasanori Noguchi
Masanori Noguchi
TSTetsuro Sasada
Tetsuro Sasada
KIKyogo Itoh
Kyogo Itoh

28 January 2003 in British Journal of Cancer
Verified
Journal Article
Open access
MNM Noguchi
M Noguchi
HKH Kikuchi
H Kikuchi
MIM Ishibashi
M Ishibashi
SNS Noda
S Noda
We addressed in this study whether quantifying the extent of disease on bone scans can predict the disease death of patients with advanced prostate cancer using computer-assisted image analysis. Pretreatment radionuclide bone scans were reviewed in 56 patients with bone metastases from prostate cancer, and the percentage of the positive area on a bone scan (%PABS) was quantified automatically using a personal computer with the NIH Image program for estimation of the accurate extent of metastatic bone lesions on a bone scan. The significance of the %PABS as well as the other known prognostic factors was evaluated using univariate and multivariate Cox proportional hazards analysis. In univariate regression analysis, the %PABS (P=0.0155), serum alkaline phosphatase (P=0.0272), the tumour grade based on biopsy (P=0.044) and the number of bone lesions on bone scans (P=0.0388) were well associated with disease-specific survival. In multivariate analysis, the %PABS (P=0.0155, relative risk ratio 2.603), but not the other factors, was the independent predictor of the disease death. These results suggest that the %PABS is a novel parameter for predicting the prognosis of patients with advanced prostatic cancer.

4 January 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MNMasanori Noguchi
Masanori Noguchi
FMFukuko Moriya
Fukuko Moriya
NKNoriko Koga
Noriko Koga
SMSatoko Matsueda
Satoko Matsueda
TSTetsuro Sasada
Tetsuro Sasada
KIKyogo Itoh
Kyogo Itoh

1 January 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MNMasanori Noguchi
Masanori Noguchi
KMKazumasa Matsumoto
Kazumasa Matsumoto
HUHirotsugu Uemura
Hirotsugu Uemura
GAGaku Arai
Gaku Arai
MEMasatoshi Eto
Masatoshi Eto
KIKyogo Itoh
Kyogo Itoh
Purpose: The prognosis of platinum-based chemotherapy–resistant metastatic urothelial cancer of the bladder remains poor. Personalized selection of the right peptides for each patient could be a novel approach for a cancer vaccine to boost anticancer immunity. Experimental Design: In this randomized, open-label, phase II study, patients ages ≥18 years with progressive bladder cancer after first-line platinum-based chemotherapy were randomly assigned (1:1) to receive personalized peptide vaccination (PPV) plus best supportive care (BSC) or BSC. PPV treatment used a maximum of four peptides chosen from 31 candidate peptides according to human leukocyte antigen types and peptide-reactive IgG titers, for 12 s.c. injections (8 injections, weekly; 4 injections, bi-weekly). The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), immune response, and toxicity. Results: Eighty patients were randomly assigned to receive either PPV plus BSC (n = 39) or BSC (n = 41). No significant improvement in PFS was noted [HR, 0.7; 95% confidence interval (CI), 0.4–1.2, P = 0.17]. For the secondary endpoints, PPV plus BSC significantly prolonged OS compared with BSC (HR, 0.58; 95% CI, 0.34–0.99, P = 0.049), with median OS of 7.9 months (95% CI, 3.5–12.0) in the PPV plus BSC and 4.1 months (95% CI, 2.8–6.9) in the BSC. PPV treatment was well tolerated, without serious adverse drug reactions. Conclusions: PPV could not prolong PFS, but OS appeared to be improved with low toxicity and immune responses. Further large-scale, randomized trials are needed to confirm these results. Clin Cancer Res; 22(1); 54–60. ©2015 AACR.

15 December 2010 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
MNMasanori Noguchi
Masanori Noguchi
TMTakashi Mine
Takashi Mine
NKNobukazu Komatsu
Nobukazu Komatsu
SSShigetaka Suekane
Shigetaka Suekane
FMFukuko Moriya
Fukuko Moriya
KIKyogo Itoh
Kyogo Itoh
To investigate immunological biomarkers to predict overall survival of advanced cancer patients under treatment with personalized peptide vaccination, correlations between overall survival and biom...